MedTrace Logo

The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients

NCT06010290 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-08-24

No results posted yet for this study

Summary

This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.

Conditions

  • Parkinson Disease

Interventions

DRUG

18F-SMBT-1

Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Qiang Xie, MD · The First Affiliated Hospital of China University of Science and Technology

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06010290 on ClinicalTrials.gov